Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long term follow-up

Canadian Journal of Gastroenterology

Volumn 12, Issue 2, 1998, Pages 125-129

  Yoshida, Eric M ^a   Ma, Mang M ^b   Davis, Jennifer E ^b   Fischer, Karl P ^b   Kneteman, Norman M ^b   Erb, Siegfried R ^b   Tyrrell, D Lorne ^b   Bain, Vincent G ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Allograft; Cirrhosis; Hepatitis B; Lamivudine resistance; Liver; Reinfection; Transplantation; YMDD mutation

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE; LIVER ENZYME; VIRUS ENZYME;

ADULT; ARTICLE; ASCITES; CASE REPORT; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HEPATIC VEIN; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; REINFECTION; TREATMENT FAILURE; VENOUS PRESSURE; VIRUS GENE; VIRUS REPLICATION;

EID: 0031939641     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1998/617039     Document Type: Article

References (32)

1. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
2. Belle SH, Beringer KC, Detre KM, et al. Trends in liver transplantation in the United States. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1993. California: UCLA Tissue Typing Laboratory, 1994:19-35.
3. Samuel D, Bismuth A, Matthieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-5.
4. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-64.
5. Terrault N, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;61:1358-64.
6. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
7. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in ziduvudine-experienced patients. A randomized controlled comparison with ziduvudine monotherapy. JAMA 1996;276:111-7.
8. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus ziduvudine compared with zalcitabine plus ziduvudine in patients with HIV infection. A randomized double-blind, placebo-controlled trial. North American HIV working party. Ann Intern Med 1996;125:161-72.
9. Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995;345:396-7. (Lett)
10. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
11. Dienstag JL, Perillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
12. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo controlled trial. Hepatology 1997;25:241-4.
13. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62:1456-62.
14. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependant DNA polymerase confers resistence to lamivudine in vivo. Hepatology 1996;24:714-7.
15. De Lamballerie X, Gallian P, De Micco PH. Evaluation of a chemiluminescent molecular hybridization assay for the detection and quantitation of hepatitis B virus-DNA in serum. New Microbiol 1995;18:207-13.
16. Bosch J, Navasa M, Garcia-Pagan JC, Delacy AM, Rhodes J. Portal hypertension. Med Clin North Am 1989;73:931-53.
17. Civitico G, Wang YY, Luscombe C, et al. Antiviral strategies in chronic hepatitis B virus infection II. Infection of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990;31:90-7.
18. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-5.
19. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
20. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after othotopic-liver transplantation. Lancet 1997;349:20-2.
21. Perillo R, Rakela J, Martin P, et al. Lamivudine for hepatitis B after liver transplantation (OLT). Hepatology 1996;24:223A.
22. Naoumov NV, Chokshi S, Smith HM, Williams R. Emergence and characterization of lamivudine-resistent hepatitis B virus variant. Hepatology 1996;24:621A.
23. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
24. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
25. Demetris HA, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Am J Pathol 1990;137:667-76.
26. Gane EJ, Portmann BC, Naoumov NV, et al. Long term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
27. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Famciclovir reduced lesion healing time in recurrent genital herpes. JAMA 1996;276:44-9.
28. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996;40:1282-4.
29. Tsiquaye KN, Sutton D, Maung M, Boyd MR. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem Chemother 1996;7:153-9.
30. Main J, Brown JL, Howells C, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1996;3:211-5.
31. Kruger M, Tillmann HL, Trautwein C, et al. Famiclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplant Surg 1996;2:253-62.
32. Rabinovitz M, Dodson F, Rakela J. Famciclovir for recurrent hepatitis B (HBV) infection after liver transplantation (OLTX). Hepatology 1996;24:624A.